Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort

Annals of Neurology

Volumn 79, Issue 4, 2016, Pages 535-547

  Willcocks, Rebecca J ^a   Rooney, William D ^b   Triplett, William T ^a   Forbes, Sean C ^a   Lott, Donovan J ^a   Senesac, Claudia R ^a   Daniels, Michael J ^c   Wang, Dah Jyuu ^d   Harrington, Ann T ^d   Tennekoon, Gihan I ^d   Russman, Barry S ^b   Finanger, Erika L ^b   Byrne, Barry J ^a   Finkel, Richard S ^e   Walter, Glenn A ^a   Sweeney, H Lee ^f   Vandenborne, Krista ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; FAT; LIPID;

6 MINUTE WALK TEST; AMBULATORY CARE; ARTICLE; BICEPS FEMORIS MUSCLE; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE DURATION; DUCHENNE MUSCULAR DYSTROPHY; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FOLLOW UP; GROUPS BY AGE; HUMAN; IMAGE ANALYSIS; LEG MUSCLE; LONGITUDINAL STUDY; LOWER LIMB; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; RELAXATION TIME; VASTUS LATERALIS MUSCLE; CLINICAL TRIAL; EXERCISE TEST; LEG; PATHOLOGY; PROCEDURES; SKELETAL MUSCLE;

BIOMARKERS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; EXERCISE TEST; HUMANS; LEG; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84975758236     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24599     Document Type: Article

References (39)

1. Mendell JR, Shilling C, Leslie ND, et al., Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012; 71: 304-313.
2. Hoffman EP, Connor EM,. Orphan drug development in muscular dystrophy: update on two large clinical trials of dystrophin rescue therapies. Discov Med 2013; 16: 233-239.
3. Fairclough RJ, Wood MJ, Davies KE,. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet 2013; 14: 373-378.
4. McDonald CM, Henricson EK, Abresch RT, et al., The 6-minute walk test and other clinical endpoints in Duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 2013; 48: 357-368.
5. McDonald CM, Henricson EK, Abresch RT, et al., The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 2013; 48: 343-356.
6. Lu QL, Cirak S, Partridge T,. What can we learn from clinical trials of exon skipping for DMD? Mol Ther Nucleic Acids 2014; 3: e152.
7. Forbes SC, Walter GA, Rooney WD, et al., Skeletal muscles of ambulant children with Duchenne muscular dystrophy: validation of multicenter study of evaluation with MR imaging and MR spectroscopy. Radiology 2013; 269: 198-207.
8. Forbes SC, Lott DJ, Finkel RS, et al., MRI/MRS evaluation of a female carrier of Duchenne muscular dystrophy. Neuromuscul Disord 2012; 22 (suppl 2): s111-s121.
9. Triplett WT, Baligand C, Forbes SC, et al., Chemical shift-based MRI to measure fat fractions in dystrophic skeletal muscle. Magn Reson Med 2014; 72: 8-19.
10. Lott DJ, Forbes SC, Mathur S, et al., Assessment of intramuscular lipid and metabolites of the lower leg using magnetic resonance spectroscopy in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2014; 24: 574-582.
11. Kinali M, Arechavala-Gomeza V, Cirak S, et al., Muscle histology vs MRI in Duchenne muscular dystrophy. Neurology 2011; 76: 346-353.
12. Marden FA, Connolly AM, Siegel MJ, Rubin DA,. Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging. Skeletal Radiol 2005; 34: 140-148.
13. Liu GC, Jong YJ, Chiang CH, Jaw TS,. Duchenne muscular dystrophy: MR grading system with functional correlation. Radiology 1993; 186: 475-480.
14. Torriani M, Townsend E, Thomas BJ, et al., Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study. Skeletal Radiol 2012; 41: 437-445.
15. Forbes SC, Willcocks RJ, Triplett WT, et al., Magnetic resonance imaging and spectroscopy assessment of lower extremity skeletal muscles in boys with duchenne muscular dystrophy: a multicenter cross sectional study. PLoS One 2014; 9: e106435.
16. Arpan I, Willcocks RJ, Forbes SC, et al., Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. Neurology 2014; 83: 974-980.
17. Wren TA, Bluml S, Tseng-Ong L, Gilsanz V,. Three-point technique of fat quantification of muscle tissue as a marker of disease progression in Duchenne muscular dystrophy: preliminary study. AJR Am J Roentgenol 2008; 190: W8-W12.
18. Frahm J, Bruhn H, Gyngell ML, et al., Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo. Magn Reson Med 1989; 9: 79-93.
19. Elliott MA, Walter GA, Swift A, et al., Spectral quantitation by principal component analysis using complex singular value decomposition. Magn Reson Med 1999; 41: 450-455.
20. Krssák M, Mlynárik V, Meyerspeer M, Moser E, Roden M,. 1H NMR relaxation times of skeletal muscle metabolites at 3 T. MAGMA 2004; 16: 155159.
21. Bonati U, Hafner P, Schädelin S, et al., Quantitative muscle MRI: A powerful surrogate outcome measure in Duchenne muscular dystrophy. Neuromuscul Disord. 2015; 25: 679-685.
22. Akima H, Lott D, Senesac C, et al., Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2012; 22: 16-25.
23. Wattjes MP, Kley RA, Fischer D,. Neuromuscular imaging in inherited muscle diseases. Eur Radiol 2010; 20: 2447-2460.
24. Bushby K, Connor E,. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond) 2011; 1: 1217-1235.
25. Lynn S, Aartsma-Rus A, Bushby K, et al., Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy. Neuromuscul Disord 2015; 25: 96-105.
26. Wokke BH, van den Bergen JC, Versluis MJ, et al., Quantitative MRI and strength measurements in the assessment of muscle quality in Duchenne muscular dystrophy. Neuromuscul Disord 2014; 24: 409-416.
27. Willis TA, Hollingsworth KG, Coombs A, et al., Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One 2013; 8: e70993.
28. Wokke BH, Bos C, Reijnierse M, et al., Comparison of dixon and T1-weighted MR methods to assess the degree of fat infiltration in duchenne muscular dystrophy patients. J Magn Reson Imaging 2013; 38: 619-624.
29. Loughran T, Higgins DM, McCallum M, et al., Improving highly accelerated fat fraction measurements for clinical trials in muscular dystrophy: origin and quantitative effect of R2∗ changes. Radiology 2015; 275: 570-578.
30. Liu CY, Redheuil A, Ouwerkerk R, Lima JA, Bluemke DA,. Myocardial fat quantification in humans: Evaluation by two-point water-fat imaging and localized proton spectroscopy. Magn Reson Med 2010; 63: 892-901.
31. Fischmann A, Gloor M, Fasler S, et al., Muscular involvement assessed by MRI correlates to motor function measurement values in oculopharyngeal muscular dystrophy. J Neurol 2011; 258: 1333-1340.
32. Loganathan R, Bilgen M, Al-Hafez B, Smirnova IV,. Characterization of alterations in diabetic myocardial tissue using high resolution MRI. Int J Cardiovasc Imaging 2006; 22: 81-90.
33. Rooney WD, Pollaro J, Forbes SC, Wang DJ, Vandenborne K, Walter GA,. Application of the extended phase graph technique to improve T2 quantitation across sites. Proc Int Soc Mag Reson Med 2011; 19: 138.
34. Azzabou N, Loureiro de Sousa P, Caldas E, Carlier PG,. Validation of a generic approach to muscle water T2 determination at 3T in fat-infiltrated skeletal muscle. J Magn Reson Imaging 2015; 41: 645-653.
35. Henricson EK, Abresch RT, Cnaan A, et al., The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 2013; 48: 55-67.
36. McDonald CM, McDonald DA, Bagley A, et al., Relationship between clinical outcome measures and parent proxy reports of health-related quality of life in ambulatory children with Duchenne muscular dystrophy. J Child Neurol 2010; 25: 1130-1144.
37. Pane M, Mazzone ES, Fanelli L, et al., Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy. Neuromuscul Disord 2014; 24: 201-206.
38. Willcocks RJ, Arpan IA, Forbes SC, et al., Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord 2014; 24: 393-401.
39. Fischmann A, Hafner P, Gloor M, et al., Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy. J Neurol 2013; 260: 969-974.